Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of pirfenidone in preparation of medicaments for controlling proliferative diseases after ophthalmologic operation and eye drops thereof

A proliferative disease, ophthalmic surgery technology, applied in blood diseases, drug combinations, extracellular fluid diseases, etc.

Active Publication Date: 2012-02-15
ZHONGSHAN OPHTHALMIC CENT SUN YAT SEN UNIV
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

With the improvement of surgical techniques and the continuous development of surgical instruments, the success rate of cataract surgery and the quality of sight recovery have been greatly improved. Most cataract patients can recover their sight through surgery. , PCO, that is, post-occurrence cataract) has caused varying degrees of visual obstruction to patients, and has become the biggest factor affecting the recovery of visual function in cataract patients after surgery.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of pirfenidone in preparation of medicaments for controlling proliferative diseases after ophthalmologic operation and eye drops thereof
  • Application of pirfenidone in preparation of medicaments for controlling proliferative diseases after ophthalmologic operation and eye drops thereof
  • Application of pirfenidone in preparation of medicaments for controlling proliferative diseases after ophthalmologic operation and eye drops thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0185] Every 100ml of pirfenidone eye drops of the present embodiment is prepared like this: the pirfenidone of 0.1g is moistened with a small amount of water for injection, then dissolves with 3ml 10% (volume fraction) acetic acid aqueous solution, adds water for injection To about 80ml, adjust the pH to about 6 with 1NNaOH, add 0.8g of sodium chloride, 0.2g of sodium citrate, and 0.002g of thimerosal, adjust to pH = 7, add sterile water for injection to 100ml, filter through 0.22μm , aseptically dispensed.

Embodiment 2

[0187] Every 100ml of pirfenidone eye drops of the present embodiment is prepared like this: the pirfenidone of 0.5g is moistened with a small amount of water for injection, then dissolves with 4ml 10% (volume fraction) acetic acid aqueous solution, adds water for injection To about 80ml, adjust the pH to about 6 with 1NNaOH, add 0.75g of sodium chloride, 0.2g of sodium citrate, and 0.002g of thimerosal, adjust to pH = 7, add sterilized water for injection to 100ml, filter through 0.22μm , aseptically dispensed.

Embodiment 3

[0189] Every 100ml of pirfenidone eye drops of the present embodiment is prepared like this: the pirfenidone of 1g is moistened with a small amount of water for injection, then dissolves with 5ml 10% (volume fraction) acetic acid aqueous solution, adds water for injection to About 80ml, adjust the pH to about 6 with 1NNaOH, add 0.7g of sodium chloride, 0.2g of sodium citrate, and 0.002g of thimerosal, adjust to pH = 7, add sterile water for injection to 100ml, filter at 0.22μm, Aseptically dispensed.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of pirfenidone in the preparation of medicaments for controlling proliferative diseases after an ophthalmologic operation and eye drops thereof. According to the invention, pirfenidone is prepared into the eye drops. Experiments show that pirfenidone has good stability and good ocular tissue permeability, can inhibit HLECs migration and propagation, and has no cytotoxicity to HLECs within the action range (0-1mg / ml). With pirfenidone being within the range of 0-1%, the eye drops are continuously applied on eyes within a month with safety and with no obvious toxic and side effect. Pirfenidone can be used to delay the generation of PCO after the rabbit corneal Phaco operation, reduce HLECs propagation and minimize the shield of PCO to an optical region. In addition, there is no obvious ocular surface injury or postoperative inflammation aggravation and severe adverse reaction after PFD is applied in the rabbit corneal Phaco operation. Therefore, pirfenidone can be used to control proliferative diseases after an ophthalmologic operation, especially posterior capsule opacification generated after a cataract surgery.

Description

Technical field: [0001] The invention belongs to the field of medicines for preventing and treating ophthalmic diseases, and in particular relates to the application of pirfenidone in the preparation of medicines for preventing and treating proliferative diseases after ophthalmic surgery, especially lens posterior capsule opacity after cataract surgery, and eye drops thereof. Background technique: [0002] Cataract is the number one cause of blindness in the world. The prevention and treatment of cataract is a key project in the prevention and treatment of blindness and public health work, and has significant practical significance. At present, the prevention and treatment of cataract is mainly surgical treatment - extracapsular cataract extraction or phacoemulsification cataract extraction combined with intraocular lens implantation. With the improvement of surgical techniques and the continuous development of surgical instruments, the success rate of cataract surgery and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4418A61P7/02
Inventor 余敏斌杨扬帆林羡钗叶成添孙国英
Owner ZHONGSHAN OPHTHALMIC CENT SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com